Antagonistic antibodies targeting the inhibitory immune-checkpoint receptor PD-1 or its
ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve …

In recent years, immunotherapy represented by immune checkpoint inhibitors (ICIs) has led
to unprecedented breakthroughs in cancer treatment. However, the fact that many tumors …

Lipids have essential biological functions in the body (eg, providing energy storage, acting
as a signaling molecule, and being a structural component of membranes); however, an …

The paradigm of surface-expressed programmed death ligand 1 (PDL1) signalling to
immune cell programmed death 1 (PD1) to inhibit antitumour immunity has helped to …

Background Continual expression of PD-L1 in tumor cells is critical for tumor immune
escape and host T cell exhaustion, however, knowledge on its clinical benefits through …

Breast cancer is the most frequent malignancy in women worldwide, and triple-negative
breast cancer (TNBC) patients have the worst prognosis and highest risk of recurrence. The …

The cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4)/B7 and programmed death 1
(PD-1)/programmed cell death-ligand 1 (PD-L1) are two most representative immune …

Abstract Programmed death-ligand 1 (PD-L1) on cancer cells engages with programmed
cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple …

Immune checkpoint blockade therapy has become a major weapon in fighting cancer.
Antibody drugs, such as anti-PD-1 and anti-PD-L1, demonstrate obvious advantages such …

Immunotherapies that target PD-1/PD-L1 axis have shown unprecedented success in a wide
variety of human cancers. PD-1 is one of the key coinhibitory receptors expressed on T cells …